Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 0.61 |
| ▸ | HTR1B | P28222 | 13/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | HTR1F | P30939 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596015 | 0.92 | HTR1D (0.63) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6598083 | 0.92 | HTR1D (0.59) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6595427 | 0.92 | HTR1D (0.59) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6595304 | 0.91 | HTR1D (0.59) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6597296 | 0.91 | HTR1D (0.76) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6598851 | 0.90 | HTR1D (0.58) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6597926 | 0.89 | HTR1D (0.71) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6595451 | 0.89 | HTR1D (0.58) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6598060 | 0.88 | HTR1D (0.55) | HTR1DHTR1BHTR1AHTR1FCHRM2 | |
| SCHEMBL6598475 | 0.88 | HTR1D (0.60) | HTR1DHTR1BCHRM2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743809-B2 | Indole Derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | claimed |
| EP-1305307-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| EP-1305307-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. Lundbeck A/S (DK) | 2003-05-02 | — | — | EP | claimed |
| WO-2002008223-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-31 | — | — | WO | claimed |
| US-6743809-B2 | Indole Derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| EP-1305307-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| EP-1305307-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. Lundbeck A/S (DK) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008223-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | DRD2, DRD3, CNR1 | HTR1D 7/4885HTR1B 18/4885HTR1A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.